Complex Information
Proteins used in this complex:
Beta-2 adrenergic receptor (Homo sapiens)
Orthosteric ligand(s) in this complex:
Kd values:
Kd according to BindingDB: 0.55 nM Original page
Kd according to BindingDB: 0.55 nM Original page
Kd according to BindingDB: 0.55 nM Original page
Kd according to BindingDB: 0.55 nM Original page
Kd according to BindingDB: 0.55 nM Original page
Kd according to BindingDB: 0.55 nM Original page
Kd according to BindingDB: 0.55 nM Original page
Kd according to BindingDB: 0.676083 nM Original page
Kd according to BindingDB: 6.3 nM Original page
Kd according to BindingDB: 0.55 nM Original page
Kd according to BindingDB: 0.676083 nM Original page
Kd according to BindingDB: 6.3 nM Original page
Kd according to BindingDB: 0.55 nM Original page
Kd according to BindingDB: 0.676083 nM Original page
Kd according to BindingDB: 6.3 nM Original page
Complex structures in which this complex is used:
Complex Structure ID: 121 using Specific State(s): Specific State ID: 5089
References for this complex:
Baker, JG. 2005. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.. British journal of pharmacology 144 (3). doi: 10.1038/sj.bjp.0706048. Available in: Pubmed Link
Baker, JG. 2005. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.. British journal of pharmacology 144 (3). doi: 10.1038/sj.bjp.0706048. Available in: Pubmed Link
Baker, JG. 2005. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.. British journal of pharmacology 144 (3). doi: 10.1038/sj.bjp.0706048. Available in: Pubmed Link
Baker, JG. 2005. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.. British journal of pharmacology 144 (3). doi: 10.1038/sj.bjp.0706048. Available in: Pubmed Link
Baker, JG. 2005. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.. British journal of pharmacology 144 (3). doi: 10.1038/sj.bjp.0706048. Available in: Pubmed Link
Baker, JG. 2005. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.. British journal of pharmacology 144 (3). doi: 10.1038/sj.bjp.0706048. Available in: Pubmed Link
Baker, JG. 2005. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.. British journal of pharmacology 144 (3). doi: 10.1038/sj.bjp.0706048. Available in: Pubmed Link
Mistry, SN; Baker, JG; Fischer, PM; Hill, SJ; Gardiner, SM; Kellam, B. 2013. Synthesis and in vitro and in vivo characterization of highly β1-selective β-adrenoceptor partial agonists.. Journal of medicinal chemistry 56 (10). doi: 10.1021/jm400348g. Available in: Pubmed Link
Soriano-Ursua, MA; Valencia-Hernandez, I; Arellano-Mendoza, MG; Correa-Basurto, J; Trujillo-Ferrara, JG. 2009. Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist.. European journal of medicinal chemistry 44 (7). doi: 10.1016/j.ejmech.2008.12.016. Available in: Pubmed Link
Baker, JG. 2005. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.. British journal of pharmacology 144 (3). doi: 10.1038/sj.bjp.0706048. Available in: Pubmed Link
Mistry, SN; Baker, JG; Fischer, PM; Hill, SJ; Gardiner, SM; Kellam, B. 2013. Synthesis and in vitro and in vivo characterization of highly β1-selective β-adrenoceptor partial agonists.. Journal of medicinal chemistry 56 (10). doi: 10.1021/jm400348g. Available in: Pubmed Link
Soriano-Ursua, MA; Valencia-Hernandez, I; Arellano-Mendoza, MG; Correa-Basurto, J; Trujillo-Ferrara, JG. 2009. Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist.. European journal of medicinal chemistry 44 (7). doi: 10.1016/j.ejmech.2008.12.016. Available in: Pubmed Link
Baker, JG. 2005. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.. British journal of pharmacology 144 (3). doi: 10.1038/sj.bjp.0706048. Available in: Pubmed Link
Mistry, SN; Baker, JG; Fischer, PM; Hill, SJ; Gardiner, SM; Kellam, B. 2013. Synthesis and in vitro and in vivo characterization of highly β1-selective β-adrenoceptor partial agonists.. Journal of medicinal chemistry 56 (10). doi: 10.1021/jm400348g. Available in: Pubmed Link
Soriano-Ursua, MA; Valencia-Hernandez, I; Arellano-Mendoza, MG; Correa-Basurto, J; Trujillo-Ferrara, JG. 2009. Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist.. European journal of medicinal chemistry 44 (7). doi: 10.1016/j.ejmech.2008.12.016. Available in: Pubmed Link
